인문학
사회과학
자연과학
공학
의약학
농수해양학
예술체육학
복합학
DBpia AI
AI 에이전트
AI 아이디어
AI 리더
AI 뷰어
Citeasy
크롬 서지관리 다운로드
지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
초록·키워드
Objective To evaluate the therapeutic efficacy and safety of pyrazinamide compared with pasiniazid in elderly patients with pulmonary tuberculosis (PTB) and to investigate their effects on serum inflammatory markers, including interferon‐gamma (IFN‐γ) and tumor necrosis factor‐alpha (TNF‐α). Methods Clinical data of 82 elderly PTB patients admitted between December 2022 and December 2023 were retrospectively analyzed. According to their documented treatment regimens, patients were divided into a control group ( n = 41, treated with pasiniazid) and a study group ( n = 41, treated with pyrazinamide). Sputum conversion rate, radiological lesion improvement, incidence of adverse drug reactions, and serum IFN‐γ and TNF‐α levels were compared between the two groups. Results After 3 and 6 months of therapy, sputum conversion rates in the pyrazinamide group were 85.37% and 95.12%, respectively, significantly higher than those in the pasiniazid group (63.41% and 80.49%, P < 0.05). The total improvement efficiency was 90.24% in the study group versus 70.73% in the control group ( P < 0.05). The incidence of adverse reactions was lower in the pyrazinamide group (14.63%) compared with the control group (36.59%, P < 0.05). After 3 months of treatment, both TNF‐α and IFN‐γ levels were markedly reduced in both groups ( P < 0.05), with greater decreases observed in the pyrazinamide group ( P < 0.001), suggesting enhanced immunomodulatory effects and better inflammatory resolution. Conclusion Pyrazinamide demonstrates superior therapeutic efficacy and lower adverse reaction rates compared with pasiniazid in elderly PTB patients. Its use is associated with significant reductions in systemic inflammatory cytokines (TNF‐α and IFN‐γ), indicating potential immunomodulatory benefits and clinical value as an adjunctive agent in tuberculosis management.
인공지능 문자 인식 모델을 통해 추출된 텍스트로, 일부 오타나 오류가 포함될 수 있으나 지속적으로 개선 중입니다.
오류를 발견하셨다면 해당 부분을 드래그한 후 ' 를 통해 신고해주세요.
오류를 발견하셨다면 해당 부분을 드래그한 후 ' 를 통해 신고해주세요.
최근 본 자료 전체보기
